Oric
IPOHOME - ORIC Pharmaceuticals
Public · South San Francisco, United States · Founded 2014 · $647.0M raised
- Headquarters
- South San Francisco, California
- Employees
- 51–200
- Founded
- 2014
- Business Model
- B2B
- Website
- oricpharma.com
- Total Funding
- $647.0M
- Last Round
- $264.0M Private EquityFeb 2026
- Rounds
- 7
- Type
- Public
About
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. The company's resistance platform targets three mechanisms: innate resistance (unaddressed oncogenic drivers), acquired resistance (induced or enriched oncogenic drivers arising in response to treatment), and bypass resistance (compensatory signaling pathways activated in response to treatment). ORIC's lead programs include rinzimetostat (ORIC-944), a PRC2 inhibitor in Phase 1b combination studies in metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant EGFR/HER2 inhibitor in Phase 1b studies across multiple NSCLC patient populations including EGFR exon 20 and PACC mutations. The company is headquartered in South San Francisco, California and is publicly traded on Nasdaq.
Summary
Oric is a Biotech company based in South San Francisco, United States, founded in 2014. It has raised $647.0M in total across 7 rounds, most recently a $264.0M Private Equity round in Feb 2026. Investors include Frazier Life Sciences, EcoR1 Capital and Venrock.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Feb 2026
Sign up to see all 8 rounds
Series A through Private Equity — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/oric"><img src="https://indexed.vc/api/badge/company/oric" alt="Oric on Indexed.vc" width="260" height="76" /></a>